AR 101

Drug Profile

AR 101

Alternative Names: Characterised Peanut Allergen (CPNA) oral immunotherapy (OIT) - Aimmune Therapeutics; Peanut allergy immunotherapy - Aimmune Therapeutics; Peanut allergy OIT - Aimmune Therapeutics

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergen Research Corporation
  • Developer Aimmune Therapeutics; Guys and St. Thomas Hospital NHS Trust
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peanut hypersensitivity

Most Recent Events

  • 06 Nov 2017 Pharmacodynamics data from the phase II ARC001 trial in Peanut hypersensitivity released by Aimmue Therapeutics
  • 31 Oct 2017 Updated adverse events and efficacy data from the phase II ARC001 trial in Peanut hypersensitivity released by Aimmue Therapeutics
  • 19 Oct 2017 Aimmune Therapeutics initiates enrolment in the RAMSES OLE trial for Peanut hypersensitivity (In children, In adolescents) in USA (NCT03337542)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top